Rankings
▼
Calendar
KMDA Q3 2024 Earnings — Kamada Ltd. Revenue & Financial Results | Market Cap Arena
KMDA
Kamada Ltd.
$520M
Q3 2024 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$42M
+10.0% YoY
Gross Profit
$17M
41.3% margin
Operating Income
$5M
12.7% margin
Net Income
$4M
9.3% margin
EPS (Diluted)
$0.07
QoQ Revenue Growth
-1.7%
Cash Flow
Operating Cash Flow
$22M
Free Cash Flow
$20M
Stock-Based Comp.
$224,000
Balance Sheet
Total Assets
$351M
Total Liabilities
$96M
Stockholders' Equity
$255M
Cash & Equivalents
$72M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$42M
$38M
+10.0%
Gross Profit
$17M
$15M
+16.4%
Operating Income
$5M
$4M
+21.2%
Net Income
$4M
$3M
+19.9%
← FY 2024
All Quarters
Q4 2024 →